{"id":15675,"date":"2020-04-06T11:24:21","date_gmt":"2020-04-06T15:24:21","guid":{"rendered":"https:\/\/medicarereport.org\/?p=15675"},"modified":"2020-04-06T11:31:19","modified_gmt":"2020-04-06T15:31:19","slug":"alzheimers-trial-screening-data-links-high-amyloid-levels-with-early-stage-disease","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=15675","title":{"rendered":"Alzheimer’s trial screening data links high amyloid levels with early stage disease"},"content":{"rendered":"

(Source – www.nia.nih.gov\/news)<\/p>\n

The first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study supports the hypothesis that higher levels of the amyloid protein in the brain represent an early stage of Alzheimer\u2019s disease. Results of an analysis of participant screening data for the study, published April 6 in JAMA Neurology, also show that amyloid burden in clinically normal older adults is associated with a family history of disease, lower cognitive test scores, and reports of declines in daily cognitive function. Major funding was provided by the National Institute on Aging (NIA), part of the National Institutes of Health; all data is now freely available to the broader research community.\u00a0 Continue to read press release here…<\/a><\/p>\n

\"\"<\/a><\/p>\n

 <\/p>\n

Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"
(Source – www.nia.nih.gov\/news) The first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study supports the hypothesis<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,26],"tags":[],"class_list":["post-15675","post","type-post","status-publish","format-standard","hentry","category-aging","category-alzheimersdementia"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/15675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15675"}],"version-history":[{"count":3,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/15675\/revisions"}],"predecessor-version":[{"id":15679,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/15675\/revisions\/15679"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}